Primorigen
1 known investors
Provides solutions for stem cell maintenance, proliferation, differentiation, and large-scale production, including recombinant substrates and antibodies.
Investors · 1
Non-dilutive funding · 14 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| NASA | Phase I | 2018 | $124.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $179.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $455.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $399.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $224.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $210.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $344.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $328.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $343.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $184.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $362.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.